QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
QQQ   353.65 (-0.16%)
AAPL   170.16 (-1.05%)
MSFT   311.72 (-0.13%)
META   299.74 (+0.26%)
GOOGL   129.83 (+0.98%)
AMZN   124.87 (-0.88%)
TSLA   237.34 (-2.78%)
NVDA   419.09 (+0.00%)
NIO   8.35 (-0.71%)
BABA   85.71 (-0.23%)
AMD   97.62 (+1.73%)
T   14.80 (-1.46%)
F   12.32 (-0.88%)
MU   67.27 (-0.99%)
CGC   0.87 (-5.79%)
GE   111.18 (+1.14%)
DIS   79.36 (-0.86%)
AMC   7.80 (-1.39%)
PFE   32.02 (-1.17%)
PYPL   57.18 (-2.97%)
NFLX   378.79 (-0.12%)
NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.44
$0.57
50-Day Range
$0.38
$0.58
52-Week Range
$0.36
$7.31
Volume
137,700 shs
Average Volume
76,300 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AYLA stock logo

About Ayala Pharmaceuticals (NASDAQ:AYLA) Stock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.


AYLA Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Recap: Ayala Pharmaceuticals Q3 Earnings
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Ayala, Advaxis Merge
Ayala Pharma, Advaxis Announce Merger - Quick Facts
See More Headlines
Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AYLA Company Calendar

Last Earnings
11/15/2021
Today
9/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYLA
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Net Income
$-40,250,000.00
Net Margins
-2,341.69%
Pretax Margin
-2,298.60%

Debt

Sales & Book Value

Annual Sales
$3.51 million
Book Value
$2.45 per share

Miscellaneous

Free Float
14,287,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
1.98
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Roni Mamluk M.D. (Age 55)
    Ph.D., Pres, CEO & Director
    Comp: $692.06k
  • Mr. Yossi Maimon CPA (Age 51)
    CPA, M.B.A., MBA, CFO, Sec. & Treasurer
    Comp: $556.43k
  • Dr. Gary B. Gordon M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $577.4k
  • Dr. Shmuel Tuvia Ph.D.
    Chief Scientific Officer
  • Ms. Irit Klipper Avni M.A.
    VP of HR
  • Ms. Dana Gelbaum M.B.A. (Age 48)
    M.Sc., Chief Bus. Officer













AYLA Stock - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" AYLA shares.
View AYLA analyst ratings
or view top-rated stocks.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.12. The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Block (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $0.50.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals (NASDAQ:AYLA) has a market capitalization of $7.46 million and generates $3.51 million in revenue each year. The company earns $-40,250,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The official website for the company is www.ayalapharma.com. The company can be reached via phone at 857-444-0553 or via email at ir@ayalapharma.com.

This page (NASDAQ:AYLA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -